| |||||||||||||||
| These "Oct-4/rtTA" mutant mice may be useful for studies of tumorigenesis and pluripotent stem cells. | |||||||||||||||
Former Names B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J (Changed: 12-APR-07 ) Type Mutant Stock; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Generation ?+N1F1 (08-DEC-07) Donating Investigator Rudolf Jaenisch, Whitehead Institute (MIT) Description
Mice heterozygous for both targeted mutations (R26-rtTA and Cola1a::tetO-Oct4) are viable and fertile. These "Oct-4/rtTA" mice express rtTA-M2, an optimized form of reverse tetracycline-controlled transactivator (rtTA) protein, in multiple tissues. In the absence of the tetracycline analog doxycycline (dox), Oct4 (Pou5f1) expression from the Col1a1 locus is not detected. Following dox administration, high Oct4 expression is induced in liver, bone marrow, stomach, intestine, and skin, with lower levels in the heart, lungs, kidney, spleen, and thymus; no expression was detected in the brain and testes. Dox-inducd activation of Oct4 results in dysplasia in epithelial tissues. These mutant mice may be useful for studies of tumorigenesis and pluripotent cells.Development
An optimized form of reverse tetracycline controlled transactivator (rtTA-M2) was introduced downstream of the Gt(ROSA)26Sor promoter by gene targeting in (C57BL/6 x 129S4Sv/Jae)F1-derived V6.5 embryonic stem (ES) cells. The modified ES cells were retargeted to allow the introduction of a tetO-Oct4 transgene into the 3? UTR of the Col1a1 locus by frt/Flpase-mediated site-specific integration. Briefly, an frt site was introduced into the 3' UTR region of Col1a1. locus by gene targeting. Correctly targeted ES cells were then cotransfected with a "flip-in plasmid" containing mouse Oct4 (Pou5f1) cDNA sequence under the control of a tetracycline responsive element (TRE or tetO) and a Flpe-recombinase plasmid to facilitate tetO-Oct4 integration into the 3' UTR region of Col1a1. The resulting ES cells were injected into B6D2F1 tetraploid blastocysts. Chimeric mice were bred together for many generations prior to arrival at The Jackson Laboratory.
| Control | ||
|---|---|---|
| 101043 B6129SF1/J | (approximate) | |
| 101045 B6129SF2/J | (approximate) | |
| Considerations for Choosing Controls | ||
Strains carrying Gt(ROSA)26Sortm1(rtTA*M2)Jae allele
006965 B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J View Strains carrying Gt(ROSA)26Sortm1(rtTA*M2)Jae (1 strain)
Strains carrying other alleles of Col1a1
002495 B6;129S4-Col1a1tm1Jae/J 002197 C57BL/6-Col1a1Mov13/J View Strains carrying other alleles of Col1a1 (2 strains)
Strains carrying other alleles of Gt(ROSA)26Sor
View Strains carrying other alleles of Gt(ROSA)26Sor (61 strains)
Strains carrying other alleles of Pou5f1
008204 B6;129S4-Pou5f1tm1Jae/J 008214 B6;129S4-Pou5f1tm2Jae/J 004654 B6;CBA-Tg(Pou5f1-EGFP)2Mnn/J View Strains carrying other alleles of Pou5f1 (3 strains)
Strains carrying other alleles of rtTA
005670 B6.Cg-Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/J 007176 B6.Cg-Tg(Pax8-rtTA2S*M2)1Koes/J 006235 B6.Cg-Tg(SFTPC-rtTA)5Jaw/J 006232 B6.Cg-Tg(Scgb1a1-rtTA)1Jaw/J 007678 B6;SJL-Tg(KRT14-rtTA)208Jek/J 010576 B6;SJL-Tg(MMTV-rtTA)4-1Jek/J 006245 C.Cg-Tg(SFTPC-rtTA)5Jaw/J 006242 C.Cg-Tg(Scgb1a1-rtTA)1Jaw/J 008099 FVB-Tg(KRT14-rtTA)F42Efu/J 004127 FVB-Tg(Nes-rtTA)306Rvs/J 006225 FVB.Cg-Tg(SFTPC-rtTA)5Jaw/J 006222 FVB.Cg-Tg(Scgb1a1-rtTA)1Jaw/J 008202 FVB/N-Tg(NPHS2-rtTA2*M2)1Jbk/J 006875 FVB/N-Tg(Tagln-rtTA)E1Jwst/J 004602 NOD.Cg-Tg(Ins2-rtTA)2Doi/DoiJ 005734 NOD/Lt-Tg(Ins2-rtTA)1Ach/AchJ 005572 STOCK Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/J 008755 STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J 008250 STOCK Tg(Ins2-rtTA)2Efr/J 005493 STOCK Tg(Tek-rtTA,TRE-lacZ)1425Tpr/J 003273 STOCK Tg(rtTAhCMV)4Bjd/J View Strains carrying other alleles of rtTA (21 strains)
Tet Expression Systems
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
- life span-post-weaning/aging
- premature death (MGI Ref ID J:98920)
- mice with doxycycline-induced ectopic Oct4 expression become morbid after 3-5 days of treatment and usually die after 5-10 days of treatment
- however, if doxycycline treatment is stopped after 5 days mice completely recover
- digestive/alimentary phenotype
- abnormal intestinal epithelium morphology (MGI Ref ID J:98920)
- after doxycline treatment, dysplastic cells are found in the entire epithelium; cells have structural and cytological dysplasia which mimics adenocarcinoma
- abnormal small intestine morphology (MGI Ref ID J:98920)
- the proximal part of the small intestine is most severely affected by doxycycline treatment with abnormal cells often almost obstructing the lumen
- after 5 days of doxycycline treatment, proliferative zone expands; postmitotic, differentiated cells lining the villus are replaced
- upon cessation of treatment, cells migrate to final destinations and differentiate upon cessation of treatment, cells migrate to final destinations and differentiate resulting in restoration of normal morphology
- abnormal stomach morphology (MGI Ref ID J:98920)
- in doxycycline treated mice, cells in the forestomach show a marked atypia and increased mitotic activity
- abnormal stomach epithelium morphology (MGI Ref ID J:98920)
- in doxycycline treated mice, forestomach epithelium is thickened and stomach shows lack of differentiation into granular and cornified cell layers compared to control mice
- the thickened epithelium consists of atypical cells with enlarged nuclei and prominent nucleoli
- abnormal stomach glandular epithelium morphology (MGI Ref ID J:98920)
- after doxycycline treatment, mice display severe dysplasia and increased proliferation
- abnormal gastric mucosa morphology (MGI Ref ID J:98920)
- pyloric mucosa contains lesions resembling high grade-dysplasia in doxycycline treated mice
- abnormal gastric gland (MGI Ref ID J:98920)
- hyperplastic fundic glands are seen in doxycycline treated mice
- stomach epithelial hyperplasia (MGI Ref ID J:98920)
- cells show atypia and increased mitotic activity throughout the squamous epithelial layer in doxycycline treated mice
- homeostasis/metabolism phenotype
- dehydration (MGI Ref ID J:98920)
- after 3-5 days of doxycycline treatment, animals display severe dehydration
- cellular phenotype
- abnormal cell proliferation (MGI Ref ID J:98920)
- abnormal cell proliferation is observed in several organs after 2 days of Oct4-induction
- however, complete reversion is seen with withdrawal of doxycycline treatment
- behavior/neurological phenotype
- lethargy (MGI Ref ID J:98920)
- animals become lethargic with doxycycline treatment within 3-5 days
- skin/coat/nails phenotype
- abnormal epidermal layer morphology (MGI Ref ID J:98920)
- after 5-10 days of doxycycline treatment, mice show mild to moderate epidermal dysplasia with a decrease in differentiation in dysplastic cells
- abnormal hair follicle morphology (MGI Ref ID J:98920)
- increased numbers of immature cells in the hair follicles of the skin are seen after 5-10 days of doxycycline
- skin tumor (MGI Ref ID J:98920)
- in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen
- hematopoietic system phenotype
- spleen atrophy (MGI Ref ID J:98920)
- in doxycycline treated mice
- thymus atrophy (MGI Ref ID J:98920)
- atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice
- immune system phenotype
- spleen atrophy (MGI Ref ID J:98920)
- in doxycycline treated mice
- thymus atrophy (MGI Ref ID J:98920)
- atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice
- tumorigenesis
- skin tumor (MGI Ref ID J:98920)
- in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Cancer Research
Other
Cell Biology Research
Transcriptional Regulation
Research Tools
Cancer Research
Tetop Tet System
Genetics Research
Mutagenesis and Transgenesis: Tetop Tet System
Mutagenesis and Transgenesis: transcriptional activation
Tet Expression Systems
tTA/rtTA Expressing Strains
tTA/rtTA Responsive Strains
| Allele Symbol | Col1a1tm2(tetO-Pou5f1)Jae | ||
|---|---|---|---|
| Allele Name | targeted mutation 2, Rudolf Jaenisch | ||
| Allele Type | Targeted (knock-in) | ||
| Common Name(s) | Col1a1::TetOP-Oct4; | ||
| Strain of Origin | (C57BL/6 x 129S4/SvJae)F1 | ||
| ES Cell Line Name | v6.5 | ||
| ES Cell Line Strain | (C57BL/6 x 129S4/SvJae)F1 | ||
| Expressed Gene | Pou5f1, POU domain, class 5, transcription factor 1, mouse, laboratory | ||
| General Note | This mutation is present in the same mouse line carrying the Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation. Expression is induced by doxycycline administration. | ||
| Molecular Note | ES cells containing the Gt(ROSA)26Sortm1(rtTA2S-M2)Jae mutation were retargeted. Cells were injected with a "flip-in plasmid" containing a tetracycline responsive element (TRE or tetO) and mouse Oct4 (Pou5f1) cDNA sequence (and a Flpe-recombinase plasmid to facilitate tetO-Oct4 integration into the 3' UTR region of Col1a1). With doxycycline treatment, Pou5f1 expression from the Col1a1 locus is widespread with high levels in skin, intestine and stomach, while lower levels are seen in the heart,spleen, thymus and several other organs. No expression is seen in the brain or testes. [MGI Ref ID J:98920] | ||
| Gene Symbol and Name | Col1a1, collagen, type I, alpha 1 | ||
| Chromosome | 11 | ||
| Gene Common Name(s) | COLIA1; Col1a-1; Cola-1; Cola1; Moloney leukemia virus 13; Mov-13; OI4; | ||
| Allele Symbol | Gt(ROSA)26Sortm1(rtTA*M2)Jae | ||
| Allele Name | targeted mutation 1, Rudolf Jaenisch | ||
| Allele Type | Targeted (knock-in) | ||
| Common Name(s) | Gt(ROSA)26Sortm1(M2rtTA)Jae; R26-M2rtTA; R26-rtTA; | ||
| Mutation Made By | Rudolf Jaenisch, Whitehead Institute (MIT) | ||
| Strain of Origin | (C57BL/6 x 129S4/SvJae)F1 | ||
| ES Cell Line Name | v6.5 | ||
| ES Cell Line Strain | (C57BL/6 x 129S4/SvJae)F1 | ||
| Site of Expression | Expresses an optimized rtTA protein (rtTA-M2). Inducible target gene expression is detected in liver, bone marrow, stomach, intestine, and skin, with lower levels in the heart, lungs, kidney, spleen, and thymus; no expression is detected in the brain and testes. | ||
| Expressed Gene | rtTA, reverse tetracycline-controlled transactivator, E. coli | ||
| The tetracycline repressor gene (Tetr), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). One mutant with a four amino acid residue change (rTetR) exhibited dependence on tetracycline for induction of the targeted gene and was used in the rtTA construct (Gossen et al, 1995). rTetr was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). | |||
| Gene Symbol and Name | Gt(ROSA)26Sor, gene trap ROSA 26, Philippe Soriano | ||
| Chromosome | 6 | ||
| Gene Common Name(s) | AV258896; Gtrgeo26; Gtrosa26; R26; ROSA26; beta geo; expressed sequence AV258896; gene trap ROSA 26; gene trap ROSA b-geo 26; | ||
| General Note |
This mutation is always used in combination with the Col1a1 | ||
| Molecular Note | An optimized form of reverse tetracycline controlled transactivator (rtTA-M2) was inserted downstream of the Gt(ROSA)26Sor promoter. This mutant form of rtTA termed M2 has five amino acid substitutions in the tetR moiety of tTA: S12G, E19G, A56P, D148E and H179R. This mutated form of transactivatory protein has increased doxycycline sensitivity. Mice have widespread expression of the rtTA-M2 protein. Doxycycline treatment induces expression of Pou5f1 from the Col1a1 locus under the control of a tetracycline-responsive element in these mice. [MGI Ref ID J:98920] | ||
Genotyping Protocols
Col1a1tm2(tetO-Pou5f1)Jae, Separated PCR
Gt(ROSA)26Sortm1sor STD, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Hochedlinger K; Yamada Y; Beard C; Jaenisch R. 2005. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121(3):465-77. [PubMed: 15882627] [MGI Ref ID J:98920]
Gt(ROSA)26Sortm1(rtTA*M2)Jae relatedBrennand K; Huangfu D; Melton D. 2007. All beta Cells Contribute Equally to Islet Growth and Maintenance. PLoS Biol 5(7):e163. [PubMed: 17535113] [MGI Ref ID J:124045]
Animal Health Reports
Room Number AX11
Colony Maintenance
Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $243.50 Female or Male Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Heterozygous for Col1a1tm2(tetO-Pou5f1)Jae $300.70 Female or Male Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Homozygous for Col1a1tm2(tetO-Pou5f1)Jae
Pairs /Price (US dollars $) Pair Genotype $487.00 Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Heterozygous for Col1a1tm2(tetO-Pou5f1)Jae x Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Heterozygous for Col1a1tm2(tetO-Pou5f1)Jae
| Pricing for International shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $316.60 Female or Male Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Heterozygous for Col1a1tm2(tetO-Pou5f1)Jae $391.00 Female or Male Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Homozygous for Col1a1tm2(tetO-Pou5f1)Jae
Pairs /Price (US dollars $) Pair Genotype $633.10 Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Heterozygous for Col1a1tm2(tetO-Pou5f1)Jae x Homozygous for Gt(ROSA)26Sortm1(rtTA*M2)Jae, Heterozygous for Col1a1tm2(tetO-Pou5f1)Jae
| Standard Supply | Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of approximately nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within two business days following order placement. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| 101043 B6129SF1/J | (approximate) | |
| 101045 B6129SF2/J | (approximate) | |
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
For additional Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.